Author

S. Meiners

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. A. Kolodziejczyk· 1 shared A. Doryab· 1 shared A. Eisenberg-Lerner· 1 shared A. Javitt· 1 shared A. Kacen· 1 shared A. Kukat· 1 shared A. Toste Rego· 1 shared A. Trifunovic· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Kolodziejczyk

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The proteasome regulator PSME4 drives immune evasion and abrogates anti-tumor immunity in NSCLC

A. Javitt, M. D. Shmueli, M. P. Kramer, A. A. Kolodziejczyk, I. J. Cohen, I. Kamer, K. Litchfield, E. Bab-Dinitz, O. Zadok, V. Neiens, A. Ulman, L. Radomir, H. Wolf-Levy, A. Eisenberg-Lerner, A. Kacen, , Y. Merbl

This paper identifies PSME4 as a proteasome regulator that suppresses anti-tumor immunity in NSCLC by inhibiting immunoproteasome activity and antigen presentation.

bioRxiv · Oct 24, 2021 · PreprintCancer Biology

Adaptive mitochondrial regulation of the proteasome

T. Meul, K. Berschneider, S. Schmitt, C. H. Mayr, L. F. Mattner, H. B. Schiller, A. Yazgili, X. Wang, C. Lukas, C. Prehn, J. Adamski, E. Graf, T. Schwarzmayr, F. Perocchi, A. Kukat, , S. Meiners

This study shows mitochondrial dysfunction reduces 26S proteasome assembly and activity, which can be reversed by aspartate or pyruvate supplementation.

bioRxiv · Apr 7, 2020 · PreprintCell Biology

Organ-restricted vascular delivery of nanoparticles for lung cancer therapy

D. A. Bolukbas, S. Datz, C. Meyer-Schwickerath, C. Morrone, A. Doryab, D. Goessl, M. Vreka, L. Yang, C. Argyo, S. H. van Rijt, M. Lindner, O. Eickelberg, T. Stoeger, O. Schmid, S. Lindstedt, , S. Meiners

This study introduces organ-restricted vascular delivery to enhance nanoparticle targeting to lung tumors, showing improved cellular uptake compared to systemic or intratracheal administration.

bioRxiv · Mar 5, 2020Pharmacology & Toxicology